NITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 159-72 C#

T05 Rec'd PCT/PTO

YOSHIHARA, N. et al.

Group Art Unit:

Serial No. 10/089,563

Examiner:

Title:

April 2, 2002 Filed:

Date: August 13, 2002

M#

KITS FOR EXTRACTING NUCLEIC ACID AND METHOD OF EXTRACTING

If "small entity," then enter half (1/2) of subtotal and subtract

NUCLEIC ACID BY USING THE KITS

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

#### RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:  Total effective claims after amendment 0 minus highest number		
Total effective claims after amendment <b>0</b> minus highest number previously paid for <b>20</b> (at least 20) = 0 x \$ 18.00		\$ 0.00
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 84.00		\$ 0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)		\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)		\$ 0.00
Terminal disclaimer enclosed, add \$ 110.00		\$ 0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) ☐ Please enter the previously unentered , filed ☐ Submission attached		\$ 0.00
	Subtotal	\$ 0.00

\$ 0.00 Rule 56 Information Disclosure Statement Filing Fee (\$180.00)

\$ 0.00 Assignment Recording Fee (\$40.00)

0.00 Other:

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

BJS:b

NIXON & VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

-\$

TOTAL FEE ENCLOSED \$

0.00

0.00



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

		ATTV	DOCKET NO.
U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT		
10/089.563	Namiko Yoshihara		159-72
10/089.503		INTERNATIONAL APPLICATION NO. PCT/JP00/05170	
	Г	I.A. FILING DATE	PRIORITY DATE
Nixon & Vanderhye	<u> </u>	08/02/2000	

Nixon & Vandernye 1100 North Glebe Road 8 th Floor Arlington, VA 22201-4714

CONFIRMATION NO. 4487
371 FORMALITIES LETTER

\*OC0000000008274568\*

Date Mailed: 06/13/2002

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

U.S. Basic National Fees

Assignee Statement

Biochemical Sequence Listing

- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- English Translation of the IA
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

DOCKETED

CLT/MATTER#	159-72
MAIL DATE	6-13-02
DUE DATE	Aug 13, 2002
FINAL DEADLINE	
DOCKETED BY	Par
DOO(\L.CD 2\	1103

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

### CHARITTA A BURT

Telephone: (703) 305-3734

### PART 1 - ATTORNEY/APPLICANT COPY

TOWN TOWN TOWN TOWN	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
U.S. APPLICATION NUMBER NO. 10/089,563	PCT/JP00/05170	159-72

FORM PCT/DO/EO/905 (371 Formalities Notice)